Diabetes Insipidus
16
4
4
9
Key Insights
Highlights
Success Rate
90% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
6.3%
1 terminated out of 16 trials
90.0%
+3.5% vs benchmark
0%
0 trials in Phase 3/4
11%
1 of 9 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 9 completed trials
Clinical Trials (16)
A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma
Plasma Oxytocin Response to Oral Estrogens in Healthy Controls and AVP-Deficiency
Wolfram Syndrome and WFS1-related Disorders International Registry and Clinical Study
Effect of Intranasal Oxytocin on Emotion Recognition and Acute Psycho-Social Stress-induced Cortisol Increase in Patients With Central Diabetes Insipidus and Healthy Controls
Use of Copeptin Measurement After Arginine Infusion for the Differential Diagnosis of Diabetes Insipidus - the CARGOx Study
Copeptin After a Subcutaneous Stimulation With Glucagon in Adults
Circulating Oxytocin Changes in Response to the Oxytocin System Stimulator MDMA in Patients With Diabetes Insipidus and Healthy Controls
Endocrine Changes and Their Correction in Heart and Lung Transplant Recipients and Donors
Shared Health Appointments and Reciprocal Enhanced Support
Metformin and Congenital Nephrogenic Diabetes Insipidus
Tracking Neurodegeneration in Early Wolfram Syndrome
Use of Copeptin in Diabetes Insipidus
Effect of Statin Treatment on Urinary AQP2 (uAQP2/01)
Copeptin in the Diagnosis and Differential Diagnosis of Diabetes Insipidus. The CoSIP-Study
Study of Novel Types of Familial Diabetes Insipidus
Study of the Pathogenesis and Pathophysiology of Familial Neurohypophyseal Diabetes Insipidus